Blueprint Medicines(BPMC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BPMC Blueprint Medicines

Halted 07-17 16:00:00 EDT

129.46

+0.00

0.00%

High129.46	Low129.46	Vol0.00
Open129.46	D1 Closing129.46	Amplitude0.00%
Mkt Cap8.38B	Tradable Cap7.79B	Total Shares64.73M
T/O385.04M	T/O Rate0.00%	Tradable Shares60.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BPMC","market":"US","secType":"STK","nameCN":"Blueprint Medicines","latestPrice":129.46,"timestamp":1752782400000,"preClose":129.46,"halted":3,"volume":0,"delay":0,"floatShares":60144183,"shares":64733629,"eps":-2.453242,"marketStatus":"Halted","change":0,"latestTime":"07-17 16:00:00 EDT","open":129.46,"high":129.46,"low":129.46,"amount":385038072.13355005,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.453242,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1430366400000,"exchange":"NASDAQ","adjPreClose":129.46,"volumeRatio":0},"requestUrl":"/m/hq/s/BPMC/tweets","defaultTab":"tweets","newsList":[{"id":"2555005154","title":"Sanofi sees 'manageable' impact from US tariffs, expects strong sales growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2555005154","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555005154?lang=en_us&edition=fundamental","pubTime":"2025-07-31 14:07","pubTimestamp":1753942059,"startTime":"0","endTime":"0","summary":"UPDATE 2-Sanofi sees 'manageable' impact from US tariffs, expects strong sales growthExpects 2025 sales to grow by high single-digit percentage Shares fall 4% on lower-than-expected earnings, higher R&D costsCFO says direct sales worth considering amid US pricing pressureRewrites throughout with CFO comments, shares in paragraph 3By Bhanvi Satija. Drugmaker Sanofi SASY.PA said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth expectations for the year, banking on expanded demand for its anti-inflammatory drug Dupixent to treat more conditions.The French firm now expects annual sales growth in the high single-digits at constant currency rates, compared to a previous forecast of mid- to high-single-digit growth.Sanofi's shares fell nearly 4%, however, as it reported lower than expected earnings for the quarter on higher research costs, though it maintained its earnings growth expectations for the year.Sanofi was also in discussions with t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nL4N3TS0JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","BPMC"],"gpt_icon":0},{"id":"2554753051","title":"BB Biotech AG Reports Q2 2025 Net Loss of CHF 100 Million; USD Share Price Up 10.2%, Currency Drag Impacts CHF Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2554753051","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554753051?lang=en_us&edition=fundamental","pubTime":"2025-07-25 13:00","pubTimestamp":1753419618,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BB Biotech AG published the original content used to generate this news brief on July 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nNDL9D9cFs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4505","LU0053671581.USD","BK4588","BK4139","AKRO","BPMC","EWTX","SRRK","BK4007","BK4585","IMCR","BK4539"],"gpt_icon":0},{"id":"2552452517","title":"Sanofi Completes Acquisition Of Blueprint Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2552452517","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552452517?lang=en_us&edition=fundamental","pubTime":"2025-07-18 14:14","pubTimestamp":1752819290,"startTime":"0","endTime":"0","summary":"July 18 (Reuters) - Sanofi SA ::*SANOFI COMPLETES ACQUISITION OF BLUEPRINT MEDICINES*TENDER OFFER FOR BLUEPRINT SHARES EXPIRED JULY 17, 2025*ACCEPTED PAYMENT FOR ALL VALIDLY TENDERED SHARES*ACQUISITIO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nRSDbksmpL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BPMC","BK4139","BK4505","LU0053671581.USD"],"gpt_icon":0},{"id":"2552451311","title":"Sanofi SA Acquires Blueprint Medicines, Establishing New Subsidiary Focused on Rare Immunology Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2552451311","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552451311?lang=en_us&edition=fundamental","pubTime":"2025-07-18 13:00","pubTimestamp":1752814818,"startTime":"0","endTime":"0","summary":"Sanofi has completed its acquisition of Blueprint Medicines Corporation, which will now operate as an indirect, wholly owned subsidiary of Sanofi. The acquisition enhances Sanofi's portfolio by adding a commercialized medicine for systemic mastocytosis  and a promising pipeline, along with expertise in rare immunological diseases. The subsidiary strengthens Sanofi's position among allergists, dermatologists, and immunologists, aiding in the advancement of its immunology pipeline. Key assets include Ayvakit/Ayvakyt, the only approved medicine for advanced and indolent SM, and elenestinib, a next-generation investigational drug for SM currently in a phase 2/3 study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL8Ddqpl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LU0053671581.USD","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","BK4139","BK4505","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BPMC"],"gpt_icon":0},{"id":"2552108845","title":"BRIEF-Sanofi Announces Extension Of Blueprint Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2552108845","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552108845?lang=en_us&edition=fundamental","pubTime":"2025-07-17 13:03","pubTimestamp":1752728612,"startTime":"0","endTime":"0","summary":"BRIEF-Sanofi Announces Extension Of Blueprint Tender OfferJuly 17 (Reuters) - Sanofi SA SASY.PA:EXTENSION OF BLUEPRINT TENDER OFFEROFFER EXPIRATION EXTENDED TO 17:00 EDST, JULY 17, 202545.85% OF BLUEP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nTUA8V5BYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BPMC","LU0053671581.USD"],"gpt_icon":0},{"id":"2552108842","title":"Rothko Merger Sub, Inc., a Sanofi Subsidiary, Extends Tender Offer for Blueprint Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2552108842","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552108842?lang=en_us&edition=fundamental","pubTime":"2025-07-17 13:00","pubTimestamp":1752728428,"startTime":"0","endTime":"0","summary":"Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi SA, has announced the extension of its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation. The offer, initially set to expire on July 16, 2025, has now been extended until July 17, 2025. Under the terms of the offer, shareholders will receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share, potentially earning up to an additional $6.00 per share, contingent upon achieving specific milestones. As of the previous deadline, approximately 45.85% of Blueprint's shares had been validly tendered, with additional shares tendered by notice of guaranteed delivery. The extension aims to meet the required conditions for completing the acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL2nW4cn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","LU0053671581.USD","BK4588","BK4505","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","BK4139","BPMC","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2550578037","title":"Christina Rossi, COO, Reports Disposal of Common Shares in Blueprint Medicines Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2550578037","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550578037?lang=en_us&edition=fundamental","pubTime":"2025-07-09 04:20","pubTimestamp":1752006035,"startTime":"0","endTime":"0","summary":"Christina Rossi, Chief Operating Officer of Blueprint Medicines Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL8dBMg3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","LU0053671581.USD","BPMC"],"gpt_icon":0},{"id":"2550457803","title":"Chief Scientific Officer Percy H. Carter Reports Disposal of Common Shares of Blueprint Medicines Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2550457803","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550457803?lang=en_us&edition=fundamental","pubTime":"2025-07-09 04:20","pubTimestamp":1752006033,"startTime":"0","endTime":"0","summary":"Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL3r523r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","BPMC","BK4505"],"gpt_icon":0},{"id":"2544049124","title":"Blueprint Medicines Corporation Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544049124","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544049124?lang=en_us&edition=fundamental","pubTime":"2025-06-20 20:05","pubTimestamp":1750421121,"startTime":"0","endTime":"0","summary":"Blueprint Medicines Corporation held its Annual Meeting of Stockholders on June 18, 2025. During the meeting, stockholders elected Jeffrey W. Albers, Mark Goldberg, M.D., and John Tsai, M.D. as Class I directors. Additionally, stockholders approved the non-binding, advisory vote on the compensation paid to the named executive officers. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL9V9ZTf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BPMC","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"2544964699","title":"Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129","url":"https://stock-news.laohu8.com/highlight/detail?id=2544964699","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544964699?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:45","pubTimestamp":1750160749,"startTime":"0","endTime":"0","summary":"Blueprint Medicines (BPMC) has an average rating of hold and mean price target of $131.53, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BPMC"],"gpt_icon":0},{"id":"2543561528","title":"Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2543561528","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543561528?lang=en_us&edition=fundamental","pubTime":"2025-06-13 06:01","pubTimestamp":1749765696,"startTime":"0","endTime":"0","summary":"Blueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT/AYVAKYT  at the 2025 European Hematology Association  Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology  Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis . The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL90ggv7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","LU0053671581.USD","BPMC"],"gpt_icon":0},{"id":"2541894093","title":"Review -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2541894093","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541894093?lang=en_us&edition=fundamental","pubTime":"2025-06-07 09:31","pubTimestamp":1749259860,"startTime":"0","endTime":"0","summary":"Markets: In a busy week, China and the U.S. sniped at each other over trade and rare-earth minerals, President Donald Trump doubled aluminum and steel tariffs to 50%, and Treasury Secretary Scott Bessent said the U.S. would \"never default on its debt.\" Stocks opened down as Treasuries climbed and May manufacturing contracted, then rose as tech rallied. The Congressional Budget Office warned the GOP tax bill would add $2.4 trillion to the deficit, and Trump finally talked to China's Xi Jinping. Stocks then plunged as Trump and Elon Musk engaged in a brutal public tweet war; Tesla fell 15%. The U.S. added 139,000 jobs in May. On the week, the Dow industrials rose 1.2%; the S&P 500, 1.5%; and the Nasdaq Composite, 2.2%.Companies: The Food and Drug Administration approved a new Moderna Covid vaccine for those over 65. Musk is selling $5 billion in debt and $300 million in shares for his artificial-intelligence start-up xAI, valuing it at $113 billion. Meta Platforms signed a 20-year deal t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235303.USD","3NVD.UK","BK4207","LU0672654240.SGD","NVDD","LU0127658192.USD","NVDY","LU0314106906.USD","LU0957808578.USD","BK4550","LU0130102774.USD","BMY","LU2360032135.SGD","LU0124676726.USD","BK4524","BNTX","PG","NVDS","LU1046421795.USD","LU0472753341.HKD","SNY","NVD2.UK","LU0985481810.HKD","LU0106831901.USD","TSYW.SI","BPMC","LU1935042991.SGD","NVDS.UK","SG9999001077.SGD","LU0157215616.USD","NVDX","TSLA","LU2543165471.USD","NVIW.SI","BK4585","NVD","NVD3.UK","LU0511384066.AUD","MRK","SG9999014898.SGD","IE00BJTD4N35.SGD","LU2097344431.USD","NVDU","SNVD.UK","2NVD.UK","LU2168564495.EUR"],"gpt_icon":1},{"id":"2541005101","title":"Chief Scientific Officer Percy H. Carter Reports Disposal of Common Shares of Blueprint Medicines Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2541005101","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541005101?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:22","pubTimestamp":1749154952,"startTime":"0","endTime":"0","summary":"Percy H. Carter, the Chief Scientific Officer of Blueprint Medicines Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL4m3bYr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer Percy H. Carter Reports Disposal of Common Shares of Blueprint Medicines Corporation","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BPMC","LU0053671581.USD"],"gpt_icon":0},{"id":"2541704350","title":"BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle","url":"https://stock-news.laohu8.com/highlight/detail?id=2541704350","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541704350?lang=en_us&edition=fundamental","pubTime":"2025-06-06 02:03","pubTimestamp":1749146604,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, CircleEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nL6N3S80F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU2237443895.HKD","SCCO","LU1235294995.USD","UDMY","IE00BK4W5M84.HKD","AVGO","CRCL","CHWY","WEC","FERG","LU0912757837.SGD","NEM","LU0198837287.USD","HL","DLTR","CDE","IE00B7SZLL34.SGD","COUR","TXN","SO","OMI","LU2362541273.HKD","CBRL","LU0345780950.USD","BK4563","CBUS","BV","LU0077335932.USD","LU0476273544.USD","PVH","BW","LU2413666426.HKD","TRUMP.USD.CC","BPMC","FCX","LU2237438978.USD","CHPT","RGNX","LTH","PHIO","FIVE","LU0345780521.USD","LU0354030438.USD","LU0724618789.USD","REGN","TSYW.SI"],"gpt_icon":1},{"id":"2541005074","title":"BUZZ-UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2541005074","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541005074?lang=en_us&edition=fundamental","pubTime":"2025-06-06 00:04","pubTimestamp":1749139472,"startTime":"0","endTime":"0","summary":"BUZZ-UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal** Brokerage UBS raises PT on biotech firm Blueprint Medicines Corp BPMC.O to $129 from $88; setting it in line with Sanofi's buyout price for the co** Maintains \"neutral\" rating** French drugmaker Sanofi SASY.PA said on Monday it has agreed to buy BPMC for up to $9.5 billion to boost its position in rare immunology diseases** UBS sees limited or no overlap in both companies' portfolios** Sanofi gains Ayvakit to treat a type of rare immunology disease called advanced and indolent systemic mastocytosis with $478.9 million revenue in 2024 - UBS ** Including session's moves, stock up 46.9% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nL3N3S8151:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BPMC","LU0053671581.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.blueprintmedicines.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0117},{"period":"1year","weight":0.3984},{"period":"ytd","weight":0.4843}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.021421},{"month":2,"riseRate":0.6,"avgChangeRate":-0.00304},{"month":3,"riseRate":0.7,"avgChangeRate":0.03296},{"month":4,"riseRate":0.4,"avgChangeRate":-0.01942},{"month":5,"riseRate":0.727273,"avgChangeRate":0.094205},{"month":6,"riseRate":0.636364,"avgChangeRate":0.080061},{"month":7,"riseRate":0.727273,"avgChangeRate":0.013767},{"month":8,"riseRate":0.7,"avgChangeRate":0.055409},{"month":9,"riseRate":0.6,"avgChangeRate":0.028138},{"month":10,"riseRate":0.4,"avgChangeRate":-0.027795},{"month":11,"riseRate":0.6,"avgChangeRate":0.051662},{"month":12,"riseRate":0.5,"avgChangeRate":0.031046}],"exchange":"NASDAQ","name":"Blueprint Medicines","nameEN":"Blueprint Medicines"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Blueprint Medicines(BPMC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Blueprint Medicines(BPMC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Blueprint Medicines,BPMC,Blueprint Medicines股票,Blueprint Medicines股票老虎,Blueprint Medicines股票老虎国际,Blueprint Medicines行情,Blueprint Medicines股票行情,Blueprint Medicines股价,Blueprint Medicines股市,Blueprint Medicines股票价格,Blueprint Medicines股票交易,Blueprint Medicines股票购买,Blueprint Medicines股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Blueprint Medicines(BPMC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Blueprint Medicines(BPMC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction